Adherence and blood pressure control in patients with primary aldosteronism

Figures & data

Table 1. Basic characteristics of studied subjects.

Number of patients (males)	50 (39)
Age (years)	64.5 ± 9
Length of follow-up (years)	7.6 ± 5
BMI (kg/m²)	31.6 ± 5
Serum K+ (mmol/l)	4.3 ± 0.4
Serum creatinine (μmol/l)	97.4 ± 28
eGFR (CKD-EPI) (ml/min/1.73 m²)	71.7 ± 18.3
Office SBP (mmHg)	140 ± 16
Office DBP (mmHg)	86 ± 10
24 h SBP (mmHg)	130 ± 12
24 h DBP (mmHg)	77 ± 9

BMI: body mass index; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure.

Table 2. Analysis of antihypertensive treatment and adherence to different antihypertensive drug classes.

	Frequency of prescribed drugs		Compliance
	(n = 50)		(calculated only from analysed medication)
	No.	%	Positive no.	Analysed no.	%
Spironolactone	22	44	21	22	95
Eplerenone	28	56	28	28	100
ACE-inhibitors	14	28	11	12	92
AT1-blockers	9	18	8	8	100
β-blockers	22	44	15	18	83
Calcium channel blockers	36	72	36	36	100
Diuretics	33	66	28	30	93
α-blockers	22	44	16	19	84
Centrally acting Sympatholytics	5	10	4	4	100

Table 3. Average dosage and plasma drug concentrations of MR antagonists.

	Average daily dose	Plasma concentration	Metabolite plasma concentration
	(mg/d)	(ng/ml)	(ng/ml)
Spironolactone	46 ± 21	10 ± 15	52 ± 38
Eplerenone	80 ± 31	987 ± 496	–